Get started
Author

Min‐Kun Chang

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects: The Journal of Clinical Pharmacology
2013 · Yanke Yu, Veronika Logovinsky, et al. · The Journal of Clinical Pharmacology · 45
Pharmacokinetic/pharmacodynamic drug–drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs
2018 · Maiko Nomoto, Cynthia A. Zamora, et al. · British Journal of Clinical Pharmacology · 28
A tandem chromatographic column method for assaying cAMP-dependent protein kinase and protein kinase C with synthetic peptide substrates
1988 · John J. Egan, Min-Kun Chang, et al. · Analytical Biochemistry · 28
An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects
2025 · Sumit Rawal, Kristin R. Wildsmith, et al. · Alzheimer Disease & Associated Disorders · 24
[p1–043]: Elenbecestat, a Novel Oral Bace Inhibitor, Has No Clinically Meaningful Effect on Qtc Interval up to a Supratherapeutic Dose of 200 Mg
2017 · Robert YK. Lai, Borje Darpo, et al. · Alzheimer s & Dementia · 7
Safety, pharmacokinetics, and pharmacodynamics in first-in-human study of a novel compound E6742, a Toll-like receptor 7 and 8 antagonist
2018 · Kenya Nakai, Sanae Yasuda, et al. · Proceedings for Annual Meeting of The Japanese Pharmacological Society · 3
PDF
[p2–003]: Elenbecestat Pharmacokinetic Drug‐drug Interactions Indicated No Dosage Adjustments Required for Most Concomitant Treatments
2017 · Bruce Albala, Robert YK. Lai, et al. · Alzheimer s & Dementia · 3
PDF
[p1–056]: Population Pharmacokinetic‐pharmacodynamic (pk/pd) Modeling of E2027, a Selective Phosphodiesterase‐9 (pde9) Inhibitor, Following Single Ascending Oral Doses in Healthy Volunteers
2017 · Edgar L. Schuck, Robert Y.K. Lai, et al. · Alzheimer s & Dementia · 2
O1‐12‐06: Phase 1 Multiple Ascending Dose (mad) Study of Phosphodiesterase‐9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies
2018 · Ishani Landry, Robert YK. Lai, et al. · Alzheimer s & Dementia · 1
P1‐055: E2027, a Novel Phosphodiesterase‐9 (pde9) Inhibitor in Development for Treatment of Dementia With Lewy Bodies (dlb), Showed No Clinically Significant Drug Interaction With Diltiazem
2018 · Ishani Landry, Robert YK. Lai, et al. · Alzheimer s & Dementia · 1
Pharmacokinetic (PK) Assessment of Perampanel Intravenous (IV) Formulation as a Bioequivalent Alternative to Oral Tablet Administration (P1.5-029)
2019 · Larisa Reyderman, Jim Ferry, et al. · Neurology
[o2–09–03]: Phase 1 Investigation Into the Safety, Tolerability, Pharmacokinetics (pk) and Pharmacodynamics (pd) of E2027, a Selective Phosphodiesterase‐9 (pde9) Inhibitor
2017 · Robert Y.K. Lai, Robert Gordon, et al. · Alzheimer s & Dementia
Reaction of sodium nitroprusside with proteins
1984 · Min‐Kun Chang · OhioLink ETD Center (Ohio Library and Information Network)
PDF
Works count: 13
Citation count: 142
H-index: 5
I10-index: 4
Year
Topic
Type